Scientists developed CAR-T cells engineered with a synthetic genetic switch designed to activate therapeutic genes only upon contact with tumors. The approach targets a core solid-tumor challenge—limiting off-tumor activity—by spatially restricting CAR-T function, aiming to improve the therapeutic index while maintaining anti-tumor activity.